Certerra Inc. is a biotechnology company that uses a proprietary Pharmacomap™ method of screening neural activation across the entire brain for drug discovery in neuroscience. Certerra's goal is to radically improve predictability from preclinical studies to human outcomes in clinical trials. Our Pharmacomap™ method is applicable for screening of novel compounds being developed for a broad spectrum of brain disorders, including neurodevelopmental, psychiatric and neurodegenerative ones, as well as repurposing of existing drugs.
Codagenix is commercializing a software-based platform for vaccine development – this platform is a Research Foundation for State University of New York technology. Codagenix has a breakthrough approach to live-attenuated vaccine design called SAVE (Synthetic Attenuated Virus Engineering). Trial and error has been the only option in vaccine development for 150 years. The SAVE platform instead relies on synthetic biology and the "re-designing" of a target virus's entire genome to yield a vaccine strain. This customization process uses software-based algorithm to 're-code' the genome of a target virus.
DepYmed Inc., is a New York based cancer therapeutic development company. DepYmed’s lead compound in development is MSI-1436C (Trodusquemine), a potent inhibitor of the enzyme PTP1B (protein tyrosine phosphatase 1B). MSI-1436C is currently in clinical development as a therapeutic candidate for HER2-positive breast cancer. A Phase 1 clinical study evaluating the safety of MSI-1436C in breast cancer patients was initiated in November 2015 at the Monter Cancer Center – a state of the art cancer treatment center and part of Northwell Health. DepYmed continues to develop the next generation of more potent PTP1B inhibitors / analogs which are currently in preclinical development in collaboration with Cold Spring Harbor Laboratory and continues to explore additional indications that may benefit from using PTP1B inhibitors as therapeutic agents.